Literature DB >> 19034521

Associations of PLA2G7 gene polymorphisms with plasma lipoprotein-associated phospholipase A2 activity and coronary heart disease in a Chinese Han population: the Beijing atherosclerosis study.

Liping Hou1, Shufeng Chen, Hongjiang Yu, Xiangfeng Lu, Jianhong Chen, Laiyuan Wang, Jianfeng Huang, Zhongjie Fan, Dongfeng Gu.   

Abstract

The human PLA2G7 gene encodes lipoprotein-associated phospholipase A(2) (Lp-PLA(2)), an emerging risk factor for cardiovascular diseases. In the present study, seven single nucleotide polymorphisms (SNPs) in the PLA2G7 gene were genotyped in 827 patients with coronary heart disease (CHD), of which 512 were patients with myocardial infarction (MI), and 947 age- and gender-matched controls in a Chinese Han population. Plasma Lp-PLA(2) activity was measured in 416 randomly selected controls and 689 randomly selected CHD patients, including 423 MI patients. Lp-PLA(2) activity in CHD and MI cases was significantly higher (233.42+/-57.66 and 234.27+/-59.51 nmol ml(-1) min(-1), respectively) than in controls (211.47+/-58.61 nmol ml(-1) min(-1)). After adjusting for traditional risk factors by logistic regression, the odds ratios for CHD and MI per 1 standard deviation increment of Lp-PLA(2) activity were 1.27 (95% CI, 1.07-1.50) and 1.27 (95% CI, 1.05-1.54), respectively. Both single SNP analysis and haplotype analysis showed that the V279F and I198T polymorphisms were significantly associated with the reduced Lp-PLA(2) activity, but neither was associated with increased CHD risk. Both univariate and multivariate analyses, adjusting effects of conventional factors, indicated that the rs13210554 T allele increased the risk of MI in this Chinese Han population. In summary, an independent association of increased plasma Lp-PLA(2) activity with CHD and MI existed in this Chinese Han Population. Although V279F and I198T mutations significantly decreased the activity of Lp-PLA(2), only the promoter rs13210554 polymorphism was associated with MI. Lp-PLA(2) activity appears to influence the CHD and MI risk in Chinese Han population.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19034521     DOI: 10.1007/s00439-008-0587-4

Source DB:  PubMed          Journal:  Hum Genet        ISSN: 0340-6717            Impact factor:   4.132


  27 in total

1.  Lipoprotein-associated phospholipase A(2), platelet-activating factor acetylhydrolase, is expressed by macrophages in human and rabbit atherosclerotic lesions.

Authors:  T Häkkinen; J S Luoma; M O Hiltunen; C H Macphee; K J Milliner; L Patel; S Q Rice; D G Tew; K Karkola; S Ylä-Herttuala
Journal:  Arterioscler Thromb Vasc Biol       Date:  1999-12       Impact factor: 8.311

Review 2.  Lipoprotein-associated phospholipase A2: a potential new risk factor for coronary artery disease and a therapeutic target.

Authors:  C H Macphee
Journal:  Curr Opin Pharmacol       Date:  2001-04       Impact factor: 5.547

3.  The Ile198Thr and Ala379Val variants of plasmatic PAF-acetylhydrolase impair catalytical activities and are associated with atopy and asthma.

Authors:  S Kruse; X Q Mao; A Heinzmann; S Blattmann; M H Roberts; S Braun; P S Gao; J Forster; J Kuehr; J M Hopkin; T Shirakawa; K A Deichmann
Journal:  Am J Hum Genet       Date:  2000-03-24       Impact factor: 11.025

4.  Deficiency of platelet-activating factor acetylhydrolase is a severity factor for asthma.

Authors:  D M Stafforini; T Numao; A Tsodikov; D Vaitkus; T Fukuda; N Watanabe; N Fueki; T M McIntyre; G A Zimmerman; S Makino; S M Prescott
Journal:  J Clin Invest       Date:  1999-04       Impact factor: 14.808

5.  A mutation in plasma platelet-activating factor acetylhydrolase (Val279-->Phe) is a genetic risk factor for stroke.

Authors:  M Hiramoto; H Yoshida; T Imaizumi; N Yoshimizu; K Satoh
Journal:  Stroke       Date:  1997-12       Impact factor: 7.914

6.  Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. West of Scotland Coronary Prevention Study Group.

Authors:  C J Packard; D S O'Reilly; M J Caslake; A D McMahon; I Ford; J Cooney; C H Macphee; K E Suckling; M Krishna; F E Wilkinson; A Rumley; G D Lowe
Journal:  N Engl J Med       Date:  2000-10-19       Impact factor: 91.245

7.  Lipoprotein-associated phospholipase A2 activity is associated with risk of coronary heart disease and ischemic stroke: the Rotterdam Study.

Authors:  Hok-Hay S Oei; Irene M van der Meer; Albert Hofman; Peter J Koudstaal; Theo Stijnen; Monique M B Breteler; Jacqueline C M Witteman
Journal:  Circulation       Date:  2005-02-08       Impact factor: 29.690

8.  Prognostic utility of lipoprotein-associated phospholipase A2 for cardiovascular outcomes in patients with stable coronary artery disease.

Authors:  Marc S Sabatine; David A Morrow; Michelle O'Donoghue; Kathleen A Jablonksi; Madeline Murguia Rice; Scott Solomon; Yves Rosenberg; Michael J Domanski; Judith Hsia
Journal:  Arterioscler Thromb Vasc Biol       Date:  2007-08-31       Impact factor: 8.311

9.  Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study.

Authors:  Christie M Ballantyne; Ron C Hoogeveen; Heejung Bang; Josef Coresh; Aaron R Folsom; Gerardo Heiss; A Richey Sharrett
Journal:  Circulation       Date:  2004-02-02       Impact factor: 29.690

10.  Comprehensive evaluation of genetic and environmental factors influencing the plasma lipoprotein-associated phospholipase A2 activity in a Japanese population.

Authors:  Shao-Yan Zhang; Hiroshi Shibata; Kenji Karino; Bin-You Wang; Shotai Kobayashi; Junichi Masuda; Toru Nabika
Journal:  Hypertens Res       Date:  2007-05       Impact factor: 3.872

View more
  29 in total

Review 1.  Modulation of oxidative stress, inflammation, and atherosclerosis by lipoprotein-associated phospholipase A2.

Authors:  Robert S Rosenson; Diana M Stafforini
Journal:  J Lipid Res       Date:  2012-06-04       Impact factor: 5.922

2.  Determination of phospholipase activity of PAF acetylhydrolase.

Authors:  Diana M Stafforini; Thomas M McIntyre
Journal:  Free Radic Biol Med       Date:  2012-05-29       Impact factor: 7.376

3.  Lipoprotein-associated phospholipase A2 and risk of incident cardiovascular disease in a multi-ethnic cohort: The multi ethnic study of atherosclerosis.

Authors:  Parveen K Garg; Robyn L McClelland; Nancy S Jenny; Michael H Criqui; Philip Greenland; Robert S Rosenson; David S Siscovick; Neal Jorgensen; Mary Cushman
Journal:  Atherosclerosis       Date:  2015-05-16       Impact factor: 5.162

Review 4.  The role of lipoprotein-associated phospholipase a₂ as a marker and potential therapeutic target in atherosclerosis.

Authors:  Ralph A H Stewart; Harvey D White
Journal:  Curr Atheroscler Rep       Date:  2011-04       Impact factor: 5.113

5.  Interaction between nonsynonymous polymorphisms in PLA2G7 gene and smoking on the risk of coronary heart disease in a Chinese population.

Authors:  Yunpeng Chi; Conghong Shi; Xiaojiang Zhang; Yang Xi
Journal:  J Thromb Thrombolysis       Date:  2018-07       Impact factor: 2.300

6.  Genome-wide association study in Han Chinese identifies three novel loci for human height.

Authors:  Yongchen Hao; Xuehui Liu; Xiangfeng Lu; Xueli Yang; Laiyuan Wang; Shufeng Chen; Hongfan Li; Jianxin Li; Jie Cao; Jichun Chen; Ying Li; Liancheng Zhao; Yongyong Shi; Chong Shen; Weili Yan; Jiang He; Jianfeng Huang; Dongfeng Gu
Journal:  Hum Genet       Date:  2013-03-03       Impact factor: 4.132

7.  Lipoprotein-associated phospholipase A(2) and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies.

Authors:  Alexander Thompson; Pei Gao; Lia Orfei; Sarah Watson; Emanuele Di Angelantonio; Stephen Kaptoge; Christie Ballantyne; Christopher P Cannon; Michael Criqui; Mary Cushman; Albert Hofman; Chris Packard; Simon G Thompson; Rory Collins; John Danesh
Journal:  Lancet       Date:  2010-05-01       Impact factor: 79.321

8.  Genome-wide association study of Lp-PLA(2) activity and mass in the Framingham Heart Study.

Authors:  Sunil Suchindran; David Rivedal; John R Guyton; Tom Milledge; Xiaoyi Gao; Ashlee Benjamin; Jennifer Rowell; Geoffrey S Ginsburg; Jeanette J McCarthy
Journal:  PLoS Genet       Date:  2010-04-29       Impact factor: 5.917

9.  Associations of platelet-activating factor acetylhydrolase (PAF-AH) gene polymorphisms with circulating PAF-AH levels and risk of coronary heart disease or blood stasis syndrome in the Chinese Han population.

Authors:  Guo-Hua Zheng; Shang-Quan Xiong; Hai-Ying Chen; Li-Juan Mei; Ting Wang
Journal:  Mol Biol Rep       Date:  2014-07-18       Impact factor: 2.316

10.  Systematic Review of the Association between Lipoprotein-Associated Phospholipase A2 and Atherosclerosis.

Authors:  Jing Liu; Yuling Hong; Yue Qi; Fan Zhao; Dong Zhao
Journal:  N Am J Med Sci (Boston)       Date:  2011-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.